Edition:
United Kingdom

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

24.72EUR
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
€24.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
53,270
52-wk High
€56.48
52-wk Low
€22.30

Latest Key Developments (Source: Significant Developments)

Celyad Announces Pricing Of 47.3 Million Dollars Global Offering
Thursday, 17 May 2018 

May 17 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES PRICING OF $47.3 MILLION GLOBAL OFFERING.PRICING OF A GLOBAL OFFERING OF 1,800,000 ORDINARY SHARES.1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE.523,913 ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES (ADSS) OFFERED IN UNITED STATES, CANADA AND CERTAIN COUNTRIES OUTSIDE OF EUROPE AT PRICE PER ADS OF USD 26.28.  Full Article

Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting
Thursday, 29 Mar 2018 

March 29 (Reuters) - CELYAD SA ::CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018.‍PRECLINICAL STUDY SHOWS ADDING CD28 OR 4-1BB TO CYAD-01 BRINGS NO BENEFIT FOR IN VITRO ACTIVITY OF RECEPTOR​.TO PRESENT UPDATE FROM THINK TRIAL, NEW SHRINK AND LINK TRIALS IN METASTATIC COLORECTAL CANCER​.‍THINK TRIAL: PRELIMINARY EVIDENCE OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CYAD-01) CLINICAL ACTIVITY​.  Full Article

Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance
Friday, 17 Nov 2017 

Nov 17 (Reuters) - CELYAD SA ::ENDED THE QUARTER WITH EUR 40 MILLION IN CASH.CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019.  Full Article

Celyad reports promising early results at 1st dose level of solid arm of THINK trial
Monday, 19 Jun 2017 

June 19 (Reuters) - CELYAD SA ::CELYAD REPORTS PROMISING EARLY RESULTS AT FIRST DOSE LEVEL OF THE SOLID ARM OF THE THINK TRIAL.TWO METASTATIC COLORECTAL CANCER PATIENTS REPORTED AS STABLE DISEASE AT 3-MONTH FOLLOW-UP(REMOVES EXTRANEOUS WORDS).NO TOXICITY SIGNALS REPORTED UP TO NOW.  Full Article

Celyad H1 loss widens to 16.9 million euros
Thursday, 25 Aug 2016 

Celyad SA : H1 loss of EUR 16.9 million ($19.05 million) versus loss of EUR 15.3 million year ago . Says ended the first half of 2016 with EUR 86 million in cash and short-term deposits .Says amount in treasury should enable to fund operating expenses and capital expenditure requirements until the end of 2018.  Full Article

Celyad says early signing agreement with ONO is because of interest of companies - conf call
Monday, 11 Jul 2016 

Celyad SA : Reason for early signing agreement with ONO Pharmaceutical <4528.T> is because of interest of companies to do so - conf call . In order for deal in US or Europe, would have to be "extremely compelling" for us at this stage - conf call . Within next 12 months we should expect second milestone - conf call . Royalty rate is same for all 3 countries - conf call . On C-Cure: discussions with EMA in Q3 - conf call . Japanese partnership has been relatively expedited - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Celyad enters into license agreement with ONO Pharmaceutical
Monday, 11 Jul 2016 

Celyad SA : Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. <4528.T> to develop allogeneic NKR-2 T-cell immunotherapy . Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan . Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories. . Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories . Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million) . Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones .Will also receive double digit royalties based on net sales of licensed product in ONO's territories.  Full Article

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT